A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL IMAGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS BY FMRI AND FDG-PET ASSESSMENTS OF MULTIPLE ORAL DOSES OF LTI-291 IN PATIENTS WITH PARKINSON'S DISEASE WITH A GBA1 MUTATION
Latest Information Update: 09 Jan 2020
At a glance
- Drugs LTI-291 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Lysosomal Therapeutics
- 04 Jul 2018 New trial record